ONO-7475 for Acute Leukemia

"This clinical trial will run for up to 12 months and its primary objective is to assess the incidence, nature, and severity of adverse events stemming from ONO-7475. Secondary objectives include determining the drug's elimination half-life; assessing the time taken for maximum plasma concentration; and establishing a Maximum Tolerated Dose (MTD)."

"This medical trial is no longer taking on new participants. The first posting was on June 26th 2017 and the most recent update occurred in July 25th 2022. Thankfully, there are many other clinical studies that may be of interest to you; 2732 trials for myelodysplastic syndromes, and 219 specifically involving ONO-7475 are currently recruiting patients."

"At present, patients can join this medical trial at 16 distinct sites. Los Angeles, Louisville and Gainesville are three of the locations that offer it; there are also 13 other cities with participating centres for those who wish to minimize their travel commitments."

"According to the clinicaltrials.gov database, this medical trial is not currently recruiting patients; it was first posted on June 26th 2017 and last updated on July 25th 2022. However, potential participants have a variety of other trials to consider as there are over 2,951 studies actively enrolling volunteers at present."

"Currently, 219 clinical trials for ONO-7475 are being conducted. Of those, 28 have reached Phase 3 of their research process. Most sites hosting these studies can be found in Boston, Massachusetts; though there is a network of 7198 different medical centres testing the treatment across multiple states."